Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase I Study Evaluating Safety, Tolerability and Pharmacokinetics of SL-11047 in Patients With Refractory Lymphoma

NCT00293488 is registered in ClinicalTrials.gov with Progen Pharmaceuticals as lead sponsor.

NCT NCT00293488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00293488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase I Study Evaluating Safety, Tolerability and Pharmacokinetics of SL-11047 in Patients With Refractory Lymphoma
Lead sponsor
Progen Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2006
Completion date
Not reported
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma